Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 55.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 39.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Outset Medical was 55.90% per year. The lowest was -23.20% per year. And the median was 11.70% per year.
Outset Medical (NAS:OM) 5-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Outset Medical 5-Year EBITDA Growth Rate Related Terms
OM vs SERA, LNSR, ZOMDF: 5-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Outset Medical's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Outset Medical 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Outset Medical's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Outset Medical's 5-Year EBITDA Growth Rate falls into.
Outset Medical 5-Year EBITDA Growth Rate Calculation
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 39.10% mean?
Outset Medical (OM) has a 5-Year EBITDA Growth Rate of 39.10% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Outset Medical and its competitors.
Is Outset Medical's 5-Year EBITDA Growth Rate too high?
Outset Medical's current 5-Year EBITDA Growth Rate is 39.10%. Overall, Outset Medical has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Outset Medical's 5-Year EBITDA Growth Rate compare to SERA and LNSR?
Outset Medical's 5-Year EBITDA Growth Rate of 39.10% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Outset Medical and its competitors. Outset Medical's current 5-Year EBITDA Growth Rate is 39.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outset Medical stock overvalued right now?
Based on GuruFocus' analysis, Outset Medical (OM) is currently considered Fairly Valued. The stock's GF Value™ is $4.06, compared to a current price of $4.29 — trading 5.7% above its estimated fair value. The current 5-Year EBITDA Growth Rate is 39.10%. Outset Medical's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Outset Medical (OM), the current 5-Year EBITDA Growth Rate is 39.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Outset Medical (OM) Overvalued in 2026?
Based on GuruFocus' analysis, Outset Medical stock appears to be overvalued.
The current stock price of $4.29 is trading 5.7% above its estimated GF Value™ of $4.06.
GuruFocus considers Outset Medical to be Fairly Valued.
Key valuation signals for OM:
5-Year EBITDA Growth Rate: 39.10%
GF Value™: $4.06 vs. price of $4.29 (5.7% above fair value)
No single metric tells the full story. See the OM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Outset Medical Inc is a medical technology company pioneering a technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
62GF Score
Get the complete analysis for OM
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OM has been successfully added to your 
